Use of teduglutide in adults with short bowel syndrome–associated intestinal failure
Open Access
- 9 June 2023
- journal article
- review article
- Published by Wiley in Nutrition in Clinical Practice
- Vol. 39 (1) , 141-153
Abstract
Short bowel syndrome (SBS) is a rare gastrointestinal disorder associated with intestinal failure (SBS‐IF) and poor health‐related outcomes. Patients with SBS‐IF are unable to absorb sufficient nutrients or fluids to maintain significantly metabolic homeostasis via oral or enteral intake alone and require long‐term intravenous supplementation (IVS), consisting of partial or total parenteral nutrition, fluids, electrolytes, or a combination of these. The goal of medical and surgical treatment for patients with SBS‐IF is to maximize intestinal remnant absorptive capacity so that the need for IVS support may eventually be reduced or eliminated. Daily subcutaneous administration of the glucagon‐like peptide 2 analog, teduglutide, has been shown to be clinically effective in reducing IVS dependence and potentially improving the health‐related quality of life of patients with SBS‐IF. The management of patients with SBS‐IF is complex and requires close monitoring. This narrative review discusses the use of teduglutide for patients with SBS‐IF in clinical practice. The screening of patient eligibility for teduglutide treatment, initiation, monitoring of efficacy and safety of treatment, adapting or weaning off IVS, and the healthcare setting needed for SBS‐IF management are described, taking into consideration data from clinical trials, observational studies, and clinical experience.Keywords
Funding Information
- Takeda Pharmaceutical Company
This publication has 65 references indexed in Scilit:
- Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndromeClinical Nutrition, 2013
- Increased Intestinal Absorption in the Era of Teduglutide and Its Impact on Management Strategies in Patients With Short Bowel Syndrome–Associated Intestinal FailureJournal of Parenteral and Enteral Nutrition, 2013
- Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal FailureGastroenterology, 2012
- Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndromeTherapeutic Advances in Gastroenterology, 2012
- Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndromeGut, 2011
- Guidelines for management of patients with a short bowelGut, 2006
- Strategies for Parenteral Nutrition Weaning in Adult Patients With Short Bowel SyndromeJournal of Clinical Gastroenterology, 2006
- Dietary and Medical Management of Short Bowel Syndrome In Adult PatientsJournal of Clinical Gastroenterology, 2006
- Intestinal adaptation after massive intestinal resectionPostgraduate Medical Journal, 2005
- Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndromeAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005